Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.81 |
| ▸ | RAB9A | P51151 | 4/20 | 0.81 |
| ▸ | TSHR | P16473 | 4/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26978013 | 0.89 | ALDH1A1 (1.00) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL16787630 | 0.88 | ALDH1A1 (0.82) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL6527991 | 0.87 | ALDH1A1 (0.81) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL1195022 | 0.87 | ALDH1A1 (0.81) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL8339357 | 0.86 | ALDH1A1 (0.60) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL1143334 | 0.86 | ALDH1A1 (1.00) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL1356015 | 0.86 | ALDH1A1 (0.79) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL3599042 | 0.85 | ALDH1A1 (0.78) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL18987325 | 0.85 | HTT (0.77) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD | |
| SCHEMBL31117147 | 0.85 | HTT (0.77) | ALDH1A1RAB9ATSHRSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265068-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265068-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230265068-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2022081573-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081573-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2022-04-21 | — | — | WO | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| EP-1893597-B1 | AMPA RECEPTOR POTENTIATORS | LILLY CO ELI (US) | 2008-11-12 | — | — | EP | disclosed |
| US-7393868-B2 | AMPA receptor potentiators | ELI LILLY AND COMPANY (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1893597-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070142441-A1 | AMPA receptor potentiators | ELI LILLY AND COMPANY | 2007-06-21 | — | — | US | disclosed |
| WO-2006132811-A2 | AMPA RECEPTOR POTENTIATORS | ELI LILLY AND COMPANY (US) | 2006-12-14 | — | — | WO | disclosed |
| US-6410533-B1 | THERAPY FOR BACTERIA INFECTIONS | GENZYME CORPORATION | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142441-A1 | AMPA receptor potentiators | GABRE, GRIN1, GRIK2 | ALDH1A1 928/4885RAB9A 2816/4885TSHR 235/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | ALDH1A1 4135/4885RAB9A 2005/4885TSHR 449/4885 |
| US-20230265068-A1 | TRANSIENT RECEPTOR POTENTIAL CANONICAL 3 INHIBITORS AND METHODS OF USE THEREOF | TRPC3, TRPV3, TRPV1 | ALDH1A1 3563/4885RAB9A 2801/4885TSHR 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.